Intellia Therapeutics, Inc.’s NTLA-2002 holds a strong position as it heads into Phase III development for hereditary angioedema (HAE), with Phase II data showing a high rate of functional cure. However, three patients continued to experience what could be HAE attacks.
On 24 October, the Cambridge, MA-based CRISPR-focused biotech published data from the Phase II portion of its Phase I/II study...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?